Related Experiment Video
Updated: Feb 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Geinsten inhibits the proliferation of VCaP castration-resistant prostate cancer cells]
Fei Li1, Yan-Feng Zhu1, Jing-Yao Chen1
1Department of Public Health, Chengdu Medical College, Chengdu, Sichuan 610500, China.
Objective:
To explore the inhibitory effect of genistein (GEN) on the proliferation of VCaP castration-resistant prostate cancer (CRPC) cells.
Methods:
VCaP CRPC cells were treated with GEN at the concentrations of 0, 12.5, 25, 50, 100, and 200 μmol/L for 24, 48, and 72 hours followed by determination of their proliferation by CCK-8 assay and their cycle by flow cytometry. The expression of Ki-67 in the cells was detected by immunocytochemistry and the levels of PSA, Cyclin D1, PCNA, and P53 determined by Western blot.
Results:
After 72 hours of treatment with GEN at 12.5, 25, 50, 100, and 200 μmol/L, the inhibition rates of the VCaP cells were (25.38±0.02)%, (31.14±0.29)%, (45.27±0.03)%, (52.19±0.05)%, and (68.21±0.19)%, respectively, all significantly higher than in the 0 μmol/L group ([10.08±0.02]%)(P<0.05). GEN caused the arrest of the VCaP cells in the G2/M phase (P<0.05) and inhibited the expression of Ki-67. The expressions of PSA, Cyclin D1, and PCNA were gradually down-regulated while that of P53 up-regulated with the increased concentration of GEN (P<0.05).
Conclusions:
GEN inhibits the proliferation of VCaP CRPC cells by arresting the cell cycle with related protein expression changes.
Insights
Genistein (GEN) effectively inhibits VCaP castration-resistant prostate cancer cell proliferation. This compound halts cell cycle progression and alters key protein expressions, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer remains a significant health concern, with castration-resistant prostate cancer (CRPC) presenting a therapeutic challenge.
- Genistein (GEN), a soy isoflavone, has demonstrated potential anti-cancer properties.
- Understanding the mechanisms by which GEN affects CRPC cells is crucial for developing novel treatments.
Purpose of the Study:
- To investigate the inhibitory effects of genistein (GEN) on the proliferation of VCaP castration-resistant prostate cancer (CRPC) cells.
- To elucidate the impact of GEN on cell cycle progression and the expression of key proteins involved in cancer cell proliferation.
Main Methods:
- VCaP CRPC cells were exposed to varying concentrations of GEN (0-200 μmol/L) for 24, 48, and 72 hours.
- Cell proliferation was assessed using the CCK-8 assay.
- Cell cycle distribution was analyzed by flow cytometry.
- Immunocytochemistry and Western blot were employed to evaluate the expression of Ki-67, PSA, Cyclin D1, PCNA, and P53.
Main Results:
- GEN significantly inhibited VCaP cell proliferation in a dose-dependent manner, with inhibition rates up to 68.21% at 200 μmol/L after 72 hours.
- GEN treatment led to G2/M phase cell cycle arrest and reduced Ki-67 expression.
- Down-regulation of PSA, Cyclin D1, and PCNA, along with up-regulation of P53, was observed with increasing GEN concentrations.
Conclusions:
- Genistein exhibits significant anti-proliferative effects on VCaP CRPC cells.
- GEN-induced inhibition is mediated through cell cycle arrest at the G2/M phase.
- Altered expression of key proteins involved in cell cycle regulation and cancer progression supports GEN's therapeutic potential in CRPC.
Related Concept Videos
Treatment Resistant Cancers
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
Resistivity
Resistance

